rheumatoid arthritis
NHS in Scotland makes rheumatoid arthritis drug available
September 14, 2021Manufacturing and Production Galapagos UK, NHS, Scotland, filgotinib, rheumatoid arthritis
The Scottish Medicines Consortium (SMC) have recommended the use of Galapagos UK’s JYSELECA® (filgotinib) for eligible patients with severe active …
NICE release new guidance on rheumatoid arthritis treatment
June 10, 2021NICE, biosimilar, rheumatoid arthritis
NICE has today published final draft guidance for the treatment of moderate rheumatoid arthritis in patients who have not responded …
AbbVie’s rheumatoid arthritis drug Rinvoq approved for NHS Scotland
February 9, 2021Manufacturing and Production AbbVie, rheumatoid arthritis
The Scottish Medicines Consortium (SMC) has recommended AbbVie’s rheumatoid arthritis (RA) drug Rinvoq (upadacitinib) for use on the NHS in …
Celltrion’s Humira biosimilar is comparable in treating rheumatoid arthritis
November 4, 2020Research and Development Humira, biosimilar, celltrion, rheumatoid arthritis
Celltrion has revealed new Phase 3 data demonstrating that its high concentration (100mg/mL) and citrate-free biosimilar CT-P17 proved comparable to …
AbbVie granted EU marketing authorisation for new arthritis drug
December 19, 2019Business Services AbbVie, EC, EU, arthritis, rheumatoid arthritis
AbbVie have announced that the European Commission (EC) have granted marketing authorisation for RINVOQ (upadacitnib). It’s a daily selective reversible …
AbbVie scoops up FDA approval for Rinvoq in moderately to severely active rheumatoid arthritis
August 19, 2019Sales and Marketing AbbVie, FDA, Rinvoq, pharma, rheumatoid arthritis
The FDA has awarded marketing authorisation to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderately to severely active rheumatoid arthritis, …
Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death
February 21, 2019Research and Development Pfizer, Xeljanz, pharma, rheumatoid arthritis
Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a …
Amgen biosimilar proves non-inferior to J&J’s Remicade in rheumatoid arthritis
June 27, 2018Research and Development, Sales and Marketing Amgen, Johnson & Jonson, Remicade, pharma, rheumatoid arthritis
Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade (infliximab), confirming that it …
Lilly’s arthritis drug hits trouble at FDA committee
April 24, 2018Manufacturing and Production, Sales and Marketing Eli Lilly, Incyte, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis
FDA’s advisory committee were openly conflicted about deciding on the safety of Eli Lilly and Incyte’s drug, baricitinib, for the …
Lilly and Incyte’s resubmission of arthritis drug data fails to assuage FDA concerns
April 20, 2018Medical Communications, Sales and Marketing Eli Lilly, FDA, Incyte, baricitinib, pharma, rheumatoid arthritis
Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib …
AbbVie’s rheumatoid arthritis drug bests even its own blockbuster Humira at Phase 3
April 11, 2018Research and Development AbbVie, Humira, pharma, rheumatoid arthritis, upadacitinib
AbbVie posted a strong showing this week from its JAK1 inhibitor upadacitinib, indicating that the drug outperformed even its own …
Death in trial blackens AbbVie’s positive rheumatoid arthritis data
December 21, 2017Research and Development AbbVie, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis
AbbVie posted strong results from its Phase 3 trial into its treatment for rheumatoid arthritis, upadacitinib, but discussions of the …
Sanofi’s arthritis treatment Kevzara secures NICE recommendation
September 25, 2017Sales and Marketing Kevzara, NICE, Sanofi, pharma, pharmaceutical, rheumatoid arthritis, sarilumab
Sanofi, along with its speciality care global business unit Sanofi Genzyme, are celebrating the news that NICE has passed its …
Questions raised after two deaths in AbbVie arthritis study
September 12, 2017Manufacturing and Production, Research and Development AbbVie, biotech, drugs, pharma, pharmaceutical, rheumatoid arthritis
AbbVie’s rheumatoid arthritis drug, upadacitinib, is the company’s big plan to manage the inevitable loss of sales from Humira, as …
FDA turns down Janssen’s sirukumab for rheumatoid arthritis
August 3, 2017Sales and Marketing FDA, Janssen, drugs, life sciences, medicine, pharma, pharmaceuticals, rheumatoid arthritis, sirukumab
Janssen has announced that it has suffered a knockback to its plans to commercialise sirukumab in the US in the …
Latest content
MHRA approves Romvimza for tenosynovial giant cell tumour
Panthera opens clinical trial site at Keele University
Santen joins inaugural Global Summit for Eye Health as partner
